Exit

University of Wyoming-backed Momentus is set to merge with SPAC Stable Road Acquisition in a deal that values the space infrastructure company at $1.2bn.

MIT's cancer therapy developer has set terms for an offering that will raise more than $185m if it floats at the top of its range.

10x Genomics has bought Harvard's genetic sequencing system provider and also revealed it closed its purchase of Stockholm University spinout CartaNA.

Dana-Farber Cancer Institute's cancer therapy developer raised $182m in an upsized IPO where it floated above its range.

Satt Erganeo-backed Open Agora offers software to run opinion surveys within enterprise software such as Slack.

The ETH Zurich software security spinout had raised at least $5.2m before it was purchased by Snyk yesterday for an undisclosed sum.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.